- Home
- ANTX vs ECOR Comparison
ANTX vs ECOR Comparison
Compare ANTX & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- ECOR
- Stock Information
- Founded
- ANTX 2017
- ECOR 2005
- Country
- ANTX United States
- ECOR United States
- Employees
- ANTX N/A
- ECOR N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ANTX Health Care
- ECOR Health Care
- Exchange
- ANTX Nasdaq
- ECOR Nasdaq
- Market Cap
- ANTX 34.4M
- ECOR 39.6M
- IPO Year
- ANTX 2022
- ECOR 2018
- Fundamental
- Price
- ANTX $1.10
- ECOR $4.91
- Analyst Decision
- ANTX Buy
- ECOR Strong Buy
- Analyst Count
- ANTX 2
- ECOR 2
- Target Price
- ANTX $2.00
- ECOR $25.50
- AVG Volume (30 Days)
- ANTX 96.8K
- ECOR 79.3K
- Earning Date
- ANTX 11-12-2025
- ECOR 11-05-2025
- Dividend Yield
- ANTX N/A
- ECOR N/A
- EPS Growth
- ANTX N/A
- ECOR N/A
- EPS
- ANTX N/A
- ECOR N/A
- Revenue
- ANTX N/A
- ECOR $29,835,000.00
- Revenue This Year
- ANTX N/A
- ECOR $24.55
- Revenue Next Year
- ANTX N/A
- ECOR $41.13
- P/E Ratio
- ANTX N/A
- ECOR N/A
- Revenue Growth
- ANTX N/A
- ECOR 27.90
- 52 Week Low
- ANTX $1.00
- ECOR $4.16
- 52 Week High
- ANTX $1.68
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- ANTX 36.23
- ECOR 41.79
- Support Level
- ANTX $1.13
- ECOR $4.47
- Resistance Level
- ANTX $1.17
- ECOR $6.61
- Average True Range (ATR)
- ANTX 0.06
- ECOR 0.46
- MACD
- ANTX -0.01
- ECOR -0.06
- Stochastic Oscillator
- ANTX 0.00
- ECOR 18.93
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.